Valentina Frusca

Valentina Frusca

Auto-generated profile, based on publicly available information

Valentina Frusca

Center for Nanotechnology Innovation@ NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro, 12, Pisa 56127, Italy; Scuola Superiore Sant'Anna, Piazza Martiri della Libertà, 33, Pisa 56127, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Nano Letters
Verified
Journal Article
Open access
AZAgata Zamborlin
Agata Zamborlin
MEMaria Laura Ermini
Maria Laura Ermini
MSMaria Summa
Maria Summa
giulia giannonegiulia giannone
giulia giannone
VFValentina Frusca
Valentina Frusca
Valerio VolianiValerio Voliani
Valerio Voliani
The intranasal administration of drugs allows an effective and noninvasive therapeutic action on the respiratory tract. In an era of rapidly increasing antimicrobial resistance, new approaches to the treatment of communicable diseases, especially lung infections, are urgently needed. Metal nanoparticles are recognized as a potential last-line defense, but limited data on the biosafety and nano/biointeractions preclude their use. Here, we quantitatively and qualitatively assess the fate and the potential risks associated with the exposure to a silver nanomaterial model (i.e., silver ultrasmall-in-nano architectures, AgNAs) after a single dose instillation. Our results highlight that the biodistribution profile and the nano/biointeractions are critically influenced by both the design of the nanomaterial and the chemical nature of the metal. Overall, our data suggest that the instillation of rationally engineered nanomaterials might be exploited to develop future treatments for (non)communicable diseases of the respiratory tract.

27 May 2024 in Advanced Materials
Verified
Journal Article
Closed access
AGAlessandra Gonnelli
Alessandra Gonnelli
MTMarine Gerbé de Thoré
Marine Gerbé de Thoré
MEMaria Laura Ermini
Maria Laura Ermini
VFValentina Frusca
Valentina Frusca
AZAgata Zamborlin
Agata Zamborlin
Valerio VolianiValerio Voliani
Valerio Voliani

5 December 2023 in ACS Applied Nano Materials
Verified
Journal Article
Open access
AZAgata Zamborlin
Agata Zamborlin
PSPatrizia Sarogni
Patrizia Sarogni
VFValentina Frusca
Valentina Frusca
AGAlessandra Gonnelli
Alessandra Gonnelli
NGNoemi Giannini
Noemi Giannini
Valerio VolianiValerio Voliani
Valerio Voliani

5 February 2024 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Open access
AGAlessandra Gonnelli
Alessandra Gonnelli
PSPatrizia Sarogni
Patrizia Sarogni
NGNoemi Giannini
Noemi Giannini
SLStefania Linsalata
Stefania Linsalata
FMFabio Di Martino
Fabio Di Martino
FPFabiola Paiar
Fabiola Paiar
Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) is characterized by high rate of recurrence, resulting in a poor survival. Standard treatments are associated with significant toxicities that impact the patient's quality of life, highlighting the urgent need for novel therapies to improve patient outcomes. On this regard, noble metal nanoparticles (NPs) are emerging as promising agents as both drug carriers and radiosensitizers. On the other hand, co-treatments based on NPs are still at the preclinical stage because of the associated metal-persistence.In this bioconvergence study, we introduce a novel strategy to exploit tumour chorioallantoic membrane models (CAMs) in radio-investigations within clinical equipment and evaluate the performance of non-persistent nanoarchitectures (NAs) in combination with radiotherapy with respect to the standard concurrent chemoradiotherapy for the treatment of HPV-negative HNSCCs. A comparable effect has been observed between the tested approaches, suggesting NAs as a potential platinum-free agent in concurrent chemoradiotherapy for HNSCCs. On a broader basis, our bioconvergence approach provides an advance for the translation of Pt-free radiosensitizer to the clinical practice, positively shifting the therapeutic vs. side effects equilibrium for the management of HNSCCs.

31 August 2024 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Open access
AZAgata Zamborlin
Agata Zamborlin
FPFrancesca Pagliari
Francesca Pagliari
MEMaria Laura Ermini
Maria Laura Ermini
VFValentina Frusca
Valentina Frusca
DGDaniel García-Calderón
Daniel García-Calderón
Valerio VolianiValerio Voliani
Valerio Voliani
Among the tumors with the highest lethality, gliomas are primary brain tumors associated with common recurrence inclined to metastasize along the neuraxis and occasionally out of the central nervous system. Even though metastasis is the main responsible for death in oncological patients, few dedicated treatments are approved. Therefore, the establishment of effective anti-metastasis agents is the final frontier in cancer research. Interestingly, some copper complexes have demonstrated promising efficacy as antimetastatic agents, but they may cause off-site effects such as the alteration of copper homeostasis in healthy tissues. Thus, the incorporation of copper-based antimetastatic agents in rationally designed nano-architectures can increase the treatment localization reducing the side effects. Here, copper complex loaded hybrid nano-architectures (CuLNAs) are presented and employed to assess the impact of an intracellular copper source on glioma cell invasiveness. The novel CuLNAs are fully characterized and exploited for cell migration modulation in a glioma cell line. The results demonstrate that CuLNAs significantly reduce cell migration without impairing cell proliferation compared to standard gold and copper NAs. A concomitant antimigratory-like regulation of the epithelial-to-mesenchymal transition genes confirmed these results, as the gene encoding for the epithelial protein E-cadherin was upregulated and the other explored mesenchymal genes were downregulated. These findings, together with the intrinsic behaviors of NAs, demonstrate that the inclusion of metal complexes in the nano-architectures is a promising approach for the composition of a family of agents with antimetastatic activity.

23 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
VLValentina De Lorenzi
Valentina De Lorenzi
NBNicoletta Brindani
Nicoletta Brindani
VFValentina Frusca
Valentina Frusca
MMMichele Menicagli
Michele Menicagli
Francesco CardarelliFrancesco Cardarelli
Francesco Cardarelli
PSPatrizia Sarogni
Patrizia Sarogni
Tumor–stroma interactions play a critical role in cancer progression, therapeutic resistance, and treatment response. Among stromal components, cancer-associated fibroblasts (CAFs) represent key regulators of tumor growth and survival and have emerged as promising therapeutic targets. In head and neck squamous cell carcinoma (HNSCC), the abundance of CAF-rich stroma contributes to disease progression and limits the efficacy of conventional therapies. Here, we investigated the antitumor activity of the topoisomerase II inhibitor ARN-24139 in Human Papilloma Virus (HPV)-positive HNSCC using three-dimensional monoculture and co-culture spheroid models. Co-culture spheroids containing fibroblasts exhibited significantly greater sensitivity to ARN-24139 than tumor mono-cultures. The acquisition of CAF-like features by fibroblasts was confirmed by α-smooth muscle actin (α-SMA) expression. At the same time, advanced two-photon imaging enabled longitudinal quantification of stromal remodeling within intact 3D spheroids enriched with EGFP-labeled fibroblasts. At sub-lethal concentrations, ARN-24139 induced marked downregulation of α-SMA, indicating stromal reprogramming, which was accompanied by increased DNA damage in adjacent tumor cells. In contrast, conventional topoisomerase inhibition with etoposide failed to reproduce these stromal effects. Collectively, these findings identify a previously unrecognized stromal-modulating activity of ARN-24139 and suggest a dose-dependent dual mode of action involving both CAF depletion and CAF reprogramming. This work highlights the therapeutic potential of targeting tumor–stroma interactions in HPV-positive HNSCC and supports further investigation of ARN-24139 in stromal-rich malignancies.